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Abstract
The pharmacological effect of opioids originates, at the cellular level, by their interaction
with the μ-opioid receptor (mOR) resulting in the regulation of voltage-gated Ca2+ channels
and inwardly rectifying K+ channels that ultimately modulate the synaptic transmission.
Recently, an alternative six trans-membrane helix isoform of mOR, (6TM-mOR) has been
identified, but its function and signaling are still largely unknown. Here, we present the struc-
tural and functional mechanisms of 6TM-mOR signaling activity upon binding to morphine.
Our data suggest that despite the similarity of binding modes of the alternative 6TM-mOR
and the dominant seven trans-membrane helix variant (7TM-mOR), the interaction with
morphine generates different dynamic responses in the two receptors, thus, promoting the
activation of different mOR-specific signaling pathways. We characterize a series of 6TM-
mOR-specific cellular responses, and observed that they are significantly different from
those for 7TM-mOR. Morphine stimulation of 6TM-mOR does not promote a cellular cAMP
response, while it increases the intracellular Ca2+ concentration and reduces the cellular K+
conductance. Our findings indicate that 6TM-mOR has a unique contribution to the cellular
opioid responses. Therefore, it should be considered as a relevant target for the develop-
ment of novel pharmacological tools and medical protocols involving the use of opioids.
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Introduction
Opioid analgesics are the most prescribed and effective drugs for the treatment of moderate
and severe pain [1]. The majority of opioid analgesics are agonists of the μ-opioid receptor
(mOR), a G protein-coupled receptor (GPCR) that modulates the basal antinociceptive
response [2–4]. The analgesic effect of opioids is associated with the mOR-mediated activation
of Gαi/o protein, which promotes the reduction of intracellular concentration of cyclic adeno-
sine monophosphate (cAMP) and intracellular Ca2+, while it stimulates an increase in cellular
K+ conductance, and ultimately leads to the inhibition of the synaptic transmission [5,6]. This
pharmacological response is generated by the interaction of opioid analgesics with the mOR
binding site that fosters a conformational rearrangement of the receptor’s intracellular loops,
and consequently mediates the activation of the Gαi/o protein [7–10]. Furthermore, ligand
stimulation of mOR activates non-canonical signaling pathways that include receptor phos-
phorylation by GPCR kinases (GRKs), and interactions with β-arrestins, which, consequently,
triggers receptor internalization process, and determines mOR down-regulation and resensiti-
zation [11–14].
Here, we report the structural and functional mechanism of a recently discovered spliced
variant of mOR, namely mOR-1K, consisting of six trans-membrane helices (6TM-mOR) [15–
18], that may contributes to the development of a cellular excitatory signaling upon activation
with morphine, the most clinically relevant mOR agonist. We demonstrate that, differently
from what has been observed in the wild type seven trans-membrane helix mOR (7TM-mOR),
the binding of morphine to 6TM-mOR does not induce the same dynamic response of the
mOR third intracellular (i3) loop, which is directly involved in the interaction with Gαi/o pro-
tein [7–10]. Consequently, the stimulation of 6TM-mOR with morphine does not induce any
intracellular cAMP response. Furthermore, we show that, upon binding to morphine, 6TM-
mOR-expressing cells are characterized by a decreased K+ conductance, and increased intracel-
lular Ca2+ concentration, which are associated with excitatory cellular response [6].
Results and Discussion
Morphine binding differentiates 6TM- and 7TM-mOR dynamic properties
In order to elucidate the structural and functional difference between 6TM- and 7TM-mOR at
the molecular level, we explore the binding properties of morphine in both mOR variants. We
model the structures of the two proteins using discrete molecular dynamics simulations [19,20]
starting from the crystallographic coordinates of the mOR chimera [21]. Then, we perform
docking calculations with MedusaDock [22,23], which properly accounts for the induced-fit
phenomenon and eliminates the possible bias originated from the starting antagonist-bound
conformation of the amino acids in the GPCR binding pockets. In both 7TM- and 6TM-mOR,
the identified bound conformation of morphine participates in van der Waals interactions with
A117, M151, W293, I296, I322, G325, and is involved in polar interactions with D147, N150,
Y326, and H297 (Fig 1, panel A), consistently with previously published data [24]. The binding
energy as estimated by MedusaScore [25] of morphine in 7TM- and 6TM-mOR is -40.3 kcal/
mol and -39.5 kcal/mol, respectively. Binding interactions are very stable in both mOR iso-
forms as computationally determined by the atomic distance between morphine and amino
acids in the orthosteric binding site of mOR isoforms (S1 and S2 Figs). In 7TM- and 6TM-
mOR, the bound conformation of morphine persists respectively within an average of ~ 0.9 Å
and ~ 0.7 Å from the initial docking conformations (Panel A S3 Fig), and the root mean square
distance (RMSD) between morphine bound conformations in the two receptors after 60-ns
simulations is equal to ~ 1.3 Å (Panel B S3 Fig). These results suggest that the binding mode of
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Fig 1. Structure and dynamics of 7TM- and 6TM-mOR in complex with morphine. A) The binding modes of morphine in 7TM- (green) and 6TM-mOR
(blue) as obtained with MedusaDock are reported on the left. The energy of binding, estimated using MedusaScore, is equal to -40.3 kcal/mol and -39.5 kcal/
mol for 7TM-mOR and 6TM-mOR, respectively. The RMSD of superimposed conformations is ~ 0.3 Å. B) The identified binding mode is very stable as
shown by the RMSD time series computed on the heavy atoms of morphine obtained from three independent MD simulations of the two morphine-bound
isoforms.C) Fluctuations of Cα atoms between the apo- (black) and morphine-bound (red) receptors. The binding of morphine increases the fluctuations of
7TM-mOR i3 loop, which is known to interact with the G protein (top). 6TM-mOR seems to be more stable than the 7TM-isoform, and the binding of morphine
does not affect the dynamic fluctuations of the i3 loop as the in 7TM-mOR isoform (low). Data are presented as mean ± standard deviation from three
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morphine in 7TM- and 6TM-mOR are energetically and geometrically very similar as also
revealed by RMSD time series of morphine’s heavy atoms computed over three independent
60-ns long molecular dynamics simulations (Fig 1, panel B). Our in silico data indicate that
morphine may interact with the opioid orthosteric binding site in both 6TM- and in 7TM-
mOR. This scenario is consistent with the lack of competition observed in 6TM-mOR between
morphine and iodobenzoylnaltrexamide (IBNTxA) or iodobenzoylnaloxamide [26,27], which
may bind to alternative 6TM-mOR sites that become accessible upon heterodimerization of
6TM-mOR with a second GPCR partner [26]. Dinstict experiments performed by different
research groups [26,28] indicate a Ki values for morphine towards 7TM-mMOR of 1.8 nM
(measured in competition assay with [D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin (DAMGO)). On
the other hand, Ki of morphine towards 6TM-mMOR is greater than 1μM (measured in com-
petition assay with IBNTxA in 6TM-mOR). The high diversity of the Ki values may be related
to the specific competition assays, as well as the peculiar properties of IBNTxA, which has
shown binding to 6TM-mOR only when the protein is co-expressed with nociceptin. [26].
Indeed, it has been recently demonstrated that 6TM-mOR can heterodimerize with a second
GPCR, like nociceptin [26] or β2-adrenergic receptor (β2AR) [18]. Thus, we cannot exclude
that the affinity, potency, and isoform-specificity of morphinans towards 6TM-mOR can vary
according to the specific oligomeric state of the receptors and the distinct GPCR partner
involved in 6TM-mOR oligomerization.
Despite the similarity of binding modes observed in our simulations, the interaction with
morphine differentiates the dynamic properties of 7TM- and 6TM-mOR’s i3 loops. Indeed,
amino acids in the i3 loop show the tendency of having higher dynamic fluctations in 7TM-,
but not in 6TM-mOR complex (Fig 1 panels C and D). Residues in the i3 loop of GPCRs
directly interact with G proteins [8], which are responsible for the initiation of the intracellular
signaling processes [9]. Although, it has been shown that GPCR conformational transitions,
involving the i3 loop and resulting in the activation/inactivation of the receptor, occur in the
microsecond scale [29,30], we speculate that the tendency of increased dynamic fluctuations of
morphine-bound 7TM-mOR’s i3 loop amino acids, observed in our simulations (tens of nano-
seconds time scale), may lower the free energy barrier of activation of the receptor as a conse-
quence of increased entropic contributions. Our data also suggest that the binding of morphine
to 6TM-mOR may not promote the same dynamic fluctuations of amino acids in the 6TM-
mOR’s i3 loop, as observed in the major mOR isoform. Under this scenario, the interaction
between the i3 loop of 6TM-mOR and the G protein might be potentially compromised as well
as the classic G protein-dependent intracellular signaling cascade. Overall, our computational
findings suggest that both mOR isoforms can interact with morphine. Nevertheless, upon
binding of morphine, 6TM-mOR does not produce the same dynamic response as 7TM-mOR,
and, thus, it may not activate a similar cellular response.
Morphine binding to 6TM-mOR does not promote cAMP response
In order to elucidate how the different dynamics of 6TM- and 7TM-mOR upon binding of
morphine affect the opioid signaling pathways, we investigated the specific cellular response to
the exposure of this drug. The absence of a morphine-mediated increase in the dynamics of the
independent MD simulations. The area under the curve values calculated over the average root mean square fluctuations (RMSF) for residues 256–283 (i.e.,
i3) are 35.02 and 47.77 for morphine-free and morphine-bound 7TM-mOR, respectively, and 33.85 and 30.57 for free and morphine-bound 6TM-mOR,
respectively. Topology map of mOR indicating helices (H), intracellular (i), and extracellular (e) loop is reported in blue. D) RMSF cumulative distributions of i3
loop amino acids are different in apo- and morphine-bound conformation of 7TM- (top) and 6TM-mOR (botton) with a p-value of 0.19 and 0.36, respectively
as determined with the Kolmogorov-Smirnov test [31]. Apo- and morphine-bound conformation data are reported as black and red lines, respectively.
Analyses are performed on the last 40 ns of simulations of three independent simulations.
doi:10.1371/journal.pone.0142826.g001
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i3 loop of 6TM-mOR suggests that the binding of morphine to 6TM-mORmay perturb the
formation of the 6TM-mOR-Gαi/o complex, and the subsequent inhibition of adenylate cyclase
(AC). The inhibition of AC is characteristic for the wild type 7TM-mOR, [5,32] and has been
implicated in the suppression of neuronal activity [6]. Previous studies showed that the stimu-
lation of 6TM-mOR with 1 μM of morphine does not promote the decrease of intracellular for-
skolin-induced cAMP levels in COS1 mamalian cells [16] as observed for the wild type 7TM-
mOR. However, since morphine dose-response testing has not been done, there is possibility
that morphine produces inhibition of AC in the 6TM-mOR dependent manner at the concen-
trations higher than 1 μM. To quantitatively test this hypothesis, we perform a cAMP-sensitive
luciferase reporter assay, which measures the morphine dose-dependent levels of intracellular
cAMP.
Luciferase reporter assay confirmed that increasing concentrations of morphine, ranging
from 10−12 to 10−4 M, do not yield any change in cAMP levels in human embryonic kidney
(HEK293) cells, transfected with 6TM-mOR, neither in the conditions of stimulated cAMP lev-
els with 100 nM of isoproterenol (to detect ligand-dependent inhibition of cAMP levels, Fig 2,
panel A), nor in unstimulated cells (to detect ligand-dependent stimulation of cAMP levels,
Fig 2, panel B). Although at the highest concentrations of morphine we observe a slight
increase in cAMP production in 6TM-mOR transfected cells (Fig 2), we also observe a compa-
rable increase in 7TM-mOR transfected cells or empty vector transfected cells. The latter
observation makes us conclude that this morphine effect is not opioid receptor specific and,
importantly, not 6TM-mOR dependent. On the contrary, 7TM-mOR transfected cells show
robust inhibition of isoprotenerol-stimulated cAMP levels (Fig 2, panel A) at IC50 of 80 nM.
This is in accordance with previous literature reporting IC50 values in a range of 10
−8–10−7 M
[33–35]. Together, these data suggest that, in contrast to 7TM-mOR that produces robust
drug-dependent cAMP inhibition, the stimulation of 6TM-mOR does not result in a mor-
phine-mediated intracellular response.
Stimulation of 6TM-mOR increases the intracellular Ca2+ concentration
Morphine-mediated cellular response results in the inhibition of pre- and postsynaptic volt-
age-gated Ca2+ channels (VGCC) [36]. Therefore, we investigate morphine-dependent dynam-
ics of the intracellular concentration of Ca2+ to further characterize the 6TM-mOR-dependent
cellular response. We have previously shown that the stimulation of 6TM-mOR results in a
morphine-dependent increase in intracellular Ca2+ response in dose dependent manner, with
administration of 10μM of morphine resulting in greatest increase [16]. Here, we monitor the
morphine-dependent intracellular Ca2+ upon stimulation with morphine of both 7TM-mOR
and 6TM-mOR isoforms dynamics in human neuroblastoma Be2C cell line using real time
Ca2+ imaging (Fig 3). In morphine dose-response studies we first establish that morphine initi-
ates detectable Ca2+ release at 1μM, gradually reaching a plateau. We then use 10μM of mor-
phine for all Ca2+ assays and electrophysiological experiments to stay at the plateau of cellular
response. A high concentration of morphine is needed for the activation of 6TM-mOR, in line
with a high Ki for morphine binding in 7TM-mOR knock-out mice [26]. Using this technique,
we confirm a stable baseline before application of morphine (proving that we are not recording
spontaneous cellular activity), and get a better understanding of the kinetics of Ca2+ influx.
During a one-hour exposure to morphine, both the percentage of responders (Fig 3, panels A
and B) and the amplitude of Ca2+ response (Fig 3, panel C) are increased in cells expressing
6TM-mOR, while cells expressing 7TM-mOR show a Ca2+ response similar to the control (i.e.,
empty vector). Given that the percentage of responding 7TM-mOR-transfected cells is similar
to control, we conclude that induction of Ca2+ current can derive from endogenous 6TM-mOR
Uncovering the Signaling Mechanism of 6TM-mOR
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expression, which is relatively high in Be2C cells [16]. Furthermore, we observe that the mor-
phine-dependent Ca2+ response is not immediate, but it gradually increases with the first spikes
appearing at 500s (Fig 3, panel C), likely indicating a VGCC activation, secondary to 6TM-
mOR stimulation. Given the lack of cAMP response observed upon 6TM-mOR stimulation,
the later Ca2+ response may derive from the signaling activity of 6TM-mOR in its heterodi-
meric form with other GPCRs, such as nocicpetin (Pasternak) or β2AR (Samoshkin), however
this hypothesis would require futher investagation. Overall, these results characterize a 6TM-
mOR-dependent Ca2+ response, and reveal an increased morphine-dependent Ca2+ response
under unstimulated Ca2+ level condition, while stimulation of 7TM-mOR under this condition
produces no response.
Fig 2. 7TM-mOR- and 6TM-mOR-dependent cAMP regulation. HEK293 cells transiently transfected with 7TM-, 6TM-mOR and empty vector (control)
expressing constructs are subjected to cAMP-sensitive luciferase reporter assay. Increasing concentrations of morphine are applied either to isoproterenol
(100 nM, for 5 min) pre-treated cells (A) or to untreated cells (B) to detect inhibition of cAMP production within 30 minutes. Data are analyzed with Prism
software (GraphPad, Software, San Diego, CA). Mean ± S.E.M., n = 3 in triplicate.
doi:10.1371/journal.pone.0142826.g002
Fig 3. 6TM-mOR transfected Be2C cells show positive Ca2+ response to the stimulation with morphine. (A) The percentage of Ca2+-responding cells
upon 10 μMmorphine treatment. Be2C cells transfected with 6TM-mOR, 7TM-mOR, or empty vector plasmids. *p<0.03, one-way ANOVA and Fisher’s LSD.
Perfusion conditions: 1 min PBS; 59 min 10 μMmorphine. (B) Time lapse images of Be2C cells transfected with 6TM-MOR at baseline (left; perfused with
PBS) and after morphine treatment (right; perfused with 10 μMmorphine). Ca2+ responses are imaged using Fura-2AM ratio-metric dye. Color scale shows
the F340/380 fluorescence intensity ratio increase. Scale bar: 100 μm. (C) Ca2+ responses of individual 6TM-mOR-transfected cells, presented as increases
in F340/380 fluorescence intensity; 10 μMmorphine was perfused between 60–3600 s (blue bar).
doi:10.1371/journal.pone.0142826.g003
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Stimulation of 6TM-mOR reduces cellular K+ conductance
The pharmacological effects of opioids have been associated with an increase in K+ conduc-
tance, which causes the hyperpolarization of neuronal cells and, ultimately, decreased neuronal
excitability [6,37]. Therefore, we investigate the 7TM-mOR- and 6TM-mOR-dependent
electrophysiological response in Be2C cells, upon stimulation with morphine. After a one-hour
administration of the drug to 7TM-mOR-transfected Be2C cells, we record a rise in an outward
current with a reversal potential near -80 mV (Fig 4, panel A), suggesting an enhanced K+ con-
ductance, which leads to a decreased cell excitability [6,37]. However, morphine stimulation of
6TM-mOR-transfected Be2C cells leads to a decrease in an outward current with a reversal
potential near -80 mV (Fig 4, panel B), suggesting a reduced K+ conductance, and, therefore an
increased cell excitability [6,37]. Averaged current density data obtained at +50 mV indicates a
significant increase in current density in response to morphine in 7TM-mOR-expressing Be2C
cells (Fig 4, panel C), whereas a significant reduction in current density at +50 mV is observed
in 6TM-mOR-transfected Be2C cells (Fig 4, panel C). Together our results characterize a
6TM-mOR-dependent cellular electrophysiological response, and reveal a reduced morphine-
induced K+ conductance, which is distinctly different from the morphine-mediated increase of
K+ conductance observed upon stimulation of 7TM-mOR.
Conclusions
Our findings point towards a unique morphine-mediated signaling pattern of 6TM-mOR,
which is largely different from what has been observed for the major 7TM-mOR isoform.
Despite the similarity of binding modes in the two receptors, morphine exhibits the tendency
to not activate the same dynamic fluctuations of the i3 loop conformation in 6TM-mOR as
observed in 7TM-mOR. As a consequence, and unlike what is observed for the major 7TM-
mOR isoform, the stimulation of 6TM-mOR by morphine does not induce a cellular cAMP
response. However, a multitude of new and unique morphine-mediated cellular responses are
induced, such as the mOR isoform-specific increase of the intracellular Ca2+ concentration,
and reduced K+ conductance, which imply the existence of a mOR isoform specific signaling
activity. It is possible that some of the observed signaling differences between the two mOR iso-
forms may results from their different sub-cellular localization. Indeed, 6TM-mOR is not con-
stitutively expressed on the plasma membrane in mammalian cells, but instead it is mainly
localized in intracellular compartments [16,17,26]. Nevertheless, it has been shown that cells
overexpressing 6TM-mOR are able to bind labeled naloxone [16]. Additionally, IBNTxA
shows high affinity binding to 6TM-mOR only in cells co-transfected with a second GPCR
partner (i.e., nociceptin), but not in cells expressing either 6TM-mOR or nociception alone
[26]. IBNTxA binding nevertheless is observed in brain tissue extracted from 7TM-mOR
knockout mice [26]. Overall, these data indicate that the lack of the first transmembrane helix
in 6TM-mOR definitely alters the cellular localization of the receptor. It cannot be excluded
that intracellularly localized 6TM-mOR can bind ligands, and initiate cellular signaling like the
sigma receptor (Sigma-1) [38] or estrogen receptor GPR30 [39]. However, it is also possible
that a yet unidentified chaperone can regulate plasma membrane co-localization, assembly,
and 6TM-mOR cellular signaling evoked by opioid ligands. Therefore, the morphine-mediated
6TM-mOR signaling may be related to the previously described physical interactions of this
receptor with a second GPCR [18,26]. Thus, it cannot be excluded that the observed cellular
responses may be related to the signaling activity of 6TM-mOR in its heterodimeric form with
β2AR [18] or nociceptin [26], and to the possible non-canonical opioid receptor signaling
pathways that may be consequentely activated through β-arrestin-dependent pathways [11–
14]. However, the elucidation of the molecular mechanisms underlying the signaling activity of
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Fig 4. Electrophysiological response of Be2C cells in response to stimulation with morphine. A)Morphine stimulation of Be2C cells transfected with
the 7TM-mOR causes a rise in an outward current with a reversal potential near -80 mV, suggesting that K+ conductance is enhanced.B)Morphine
stimulation of Be2C cells transfected with the 6TM-mOR leads to a decrease in an outward current with a reversal potential near -80 mV, suggesting that K+
conductance is reduced.C) Averaged current density data obtained at +50 mV indicates an increase in current density in response to morphine in 7TM-
mOR-expressing Be2C (p = 0.04), while a significant reduction in current density is observed in 6TM-mOR-transfected Be2C cells (p = 0.04). For treated cells
10 μM of morphine were added to growth medium one hour before recordings.
doi:10.1371/journal.pone.0142826.g004
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the heterodimer goes beyond the scope of the presented manuscript and will require further
investigation. In conclusion, our data indicate that 6TM-mOR may directly compete with
7TM-mOR for the binding of morphine without generating the same cellular response. There-
fore, we foresee 6TM-mOR as a unique player in cellular opioid responses that might constitute
a new target for novel pharmacological strategies in pain managements protocols that consider
the use of opioid drugs.
Materials and Methods
Generation of structural models of 7TM- and 6TM-mOR
We generate the structural models of 7TM- and 6TM-mOR by applying minor changes to the
crystallographic coordinates of the 7TM-mOR chimera, as available from the Protein Data
Bank [40] (PDB ID: 4DKL) at 2.80 Å resolution [21]. The mouse isoform of mOR (PDB ID:
4DKL) has 93.75% global homology with the human variants, and 100% homology at the level
of the binding site and the i3 loop. Therefore, we model 7TM-mOR by removing the coordi-
nates of the co-crystallized morphinan antagonist β-funaltrexamine (β-FNA) and the T4 lyso-
zyme, which replaces the i3 loop between helices 5 and 6 in the opioid receptor. Additionally,
in order to obtain the structural model of 6TM-mOR, we remove the first trans-membrane
helix (i.e., fromM65 to K98). For both 7TM- and 6TM-mOR models we manually reconstruct
the amino acid sequence of the i3 loop (i.e., from M264 to K269) and model its conformation
using discrete molecular dynamics (DMD) [19,20]. In DMD, atomic interactions are approxi-
mated by square-well potentials. The simulation engine solves a series of two-body collisions,
in which colliding atoms’ velocities change instantaneously according to the conservation laws
of energy, momentum, and angular momentum. A united atom representation is used to
model protein structure, and the Lazaridis-Karplus implicit solvation model [41] is adopted to
account for the solvation energy, while temperature is controlled with the Andersen thermostat
[42]. For both 7TM- and 6TM-mOR, we run a short DMD simulation (100,000 steps, i.e., ~ 5
ns) at the temperature of 0.5 kcal/mol kB (~ 300 K). During the simulation, all atomic coordi-
nates from the crystal structure are harmonically constrained, and only atoms constituting the
i3 loop and the connecting peptide bonds are allowed to move freely. We generate a total num-
ber of 1,000 i3 loop conformations for 7TM- and 6TM-mOR and, in order to discriminate dif-
ferent conformations, we perform a cluster analysis based on the root mean squared distance
(RMSD) of backbone Cα atoms (applied cutoff of 2.5 Å, chosen as a good quality threshold to
define high-resolution crystal structures). Finally, we retrieve the centroids of the most popu-
lated cluster as the representative conformation of the i3 loop in the 7TM- and 6TM-mOR
structural models. We then assess the quality of our generated models using Gaia (http://troll.
med.unc.edu/chiron/login.php, [43]), which compares their intrinsic structural properties to
high-resolution crystal structures. No critical issues are found in our 7TM- and 6TM-mOR
models, which are further used for docking and molecular dynamics studies.
Docking of morphine in 7TM- and 6TM-mOR
We adopt the obtained structural models of 7TM- and 6TM-mOR for our docking calcula-
tions, while structures of ligands are generated using the LigPrep (v. 2.8) module available in
Maestro (Schroedinger, LLC New York). Docking calculations are performed using Medusa-
Dock [22,23], our in-house developed software that simultaneously models the flexibility of
both ligand and receptor. MedusaDock properly accounts for the induced fit phenomenon
upon ligand binding and, thus, it is not sensitive to the starting conformation of amino acids in
the GPCR’s binding pocket. Therefore, our docking results are not biased by the starting con-
formation of the 7TM-mOR binding site in complex with the antagonist β-FNA. During
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docking, we retrieve representative conformations of morphine in complex with 7TM- and
6TM-mOR by combining the values of MedusaScore [25], a physical force field based scoring
function accounting for the protein-ligand interaction energy, with a hierarchical cluster analy-
sis of the top-ranked ligand conformations. In further detail, we run 2,000 independent dock-
ing calculations and collect the top-scoring (i.e., lowest energy) conformations of morphine in
complex with 7TM- and 6TM-mOR. We cluster the ensemble of docking solutions according
to the RMSD of the ligand’s heavy atoms, and the centroid of the most populated cluster is cho-
sen as the representative conformation of morphine bound to the two receptors. Since Medusa-
Dock does not account for the formation of a covalent bond between ligand and receptor, we
are unable to properly evaluate the binding conformation of the co-crystallized molecule β-
FNA in a covalent complex with 7TM-mOR. However, we can estimate the performance of
our procedure by comparing the relative orientations of the morphinan cores of our docking
solutions with respect to the crystallographic pose of β-FNA (panel A S4 Fig). The RMSD com-
puted over the morphinan’s heavy atoms of morphine and β-FNA is 3.8 Å, only 1 Å over the
atomic resolution of the crystallographic structure (i.e., 2.8 Å). Such discrepancy is mainly due
to the lack of substituents on the morphinan core of morphine that can deeply penetrate into
the 7TM-mOR binding pocket. On the other hand, the bound conformation of the β-FNA is
more external because of the steric hindrance exerted by the cyclopropylmethyl substituent
and the covalent bond with K233 mediated by the enoate chain. Despite the occurrence of
these differences, the relative orientation of the morphinan core is kept in both morphine and
β-FNA bound conformations (panel B, S4 Fig). Therefore, the described procedure is able to
correctly reproduce the orientation of the morphinan core of opioids in 7TM-mOR binding
site as also pointed out by the comparison with previously published docking solutions (panel
C S4 Fig and S1 Table, [7]).
Molecular dynamics simulations of 7TM- and 6TM-mOR
Molecular dynamics (MD) simulations of free and opioid-bound 7TM- and 6TM-mOR are
performed using GROMACS [44] and CHARMM36 force field [45], including additional
parameters for morphine and lipids. We embed the structures of apo- and morphine-bound
opioid isoforms in a lipid bilayer accounting for the presence of water and physiological salt
concentration (NaCl). The TIP3P model [46] is employed for explicit water molecules. For the
lipid membrane we adopt the 1,2-dipalmitoyl-sn-phosphatidylcoline (DPPC) CHARMM36
parameters, which effectively reproduce a series of experimentally determined physicochemical
features of lipid bilayers [47]. CHARMM parameters for morphine are derived using the Swis-
sParam website (http://www.swissparam.ch/) [48]. Isothermal-isobaric (NPT) simulations are
carried out with a time step of 2 fs and periodic boundary conditions to eliminate the finite size
effect (box dimensions 143 x 143 x 162 Å, containing ~ 205,000 atoms). Particle mesh Ewald
sum (PME) [49] is employed to model electrostatics, using a 10 Å cutoff distance and 12 Å grid
spacing. We adopt the Lennard-Jones switching function over a range of 8 to 12 Å to account
for van der Waals interactions, and LINCS algorithm to constrain bond lengths [50]. During
the simulation, pressure is set to 1 atm and temperature to 300 K using Parrinello-Rahman
barostat [51] and Nosé-Hoover thermostat [52], respectively. To ensure the packing of lipids
around the receptors, we impose harmonic constraints on the protein structures and run short
simulations (i.e., 0.5 ns each) as described by Serhoijos et al. [7]. For the four systems under
investigation, we perform a 20 ns-long equilibration run and, from the last 10 ns of each simu-
lation, we randomly extract three snapshots that are then resubmitted for three further inde-
pendent 60 ns-long production runs. Finally, the last 40 ns of the MD simulations are taken
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into account for the analysis of both apo- and morphine-bound 7TM-mOR and 6TM-mOR
dynamics.
cAMP assay
Human HEK293 cells are transiently cotransfected with GloSensor-22F cAMP-sensitive con-
stract and with pIRES-EGFP-7TM-mOR, -6TM-mOR or empty vector (control) expressing
constructs, and subjected to cAMP-sensitive luciferase reporter assay (Promega), as described
by Serhoijos et al. [7]. Briefly, the day after transfection (24 hr), cells are seeded in 384-well
plates. The following day cells pretreated with 100 nM isoproterenol are challenged with mor-
phine at different concentrations and luminescence is recorded on a Victor plate reader (Perkin
Elmer). Transfection efficiency is monitored across experiments by EGFP basal level expres-
sion, and is comparable in all conditions. We further check the protein expression levels in
HEK293 using FLAG-tagged constructs (S5 Fig). However, cAMP and Ca2+ experiments (next
section) are performed in cells expressing untagged proteins to avoid generation of potentially
false results in the case that FLAG interferes with mOR receptor functions.
Ca2+ measurement
Human Be2C cells (ATCC, Manassas, VA, USA) are seeded onto glass coverslips for 24 hours
and then transfected with human pIRES-EGFP-7TM-mOR, -6TM-mOR expression constructs
or empty vector using Lipofectamine 2000 reagent (Life Technologies Inc., USA) with as
described previously [16]. Be2C cells are chosen for this assay because these cells have a robust
Ca2+ respond and express all cellular components required for its activation. After 24 hours
Be2C cells are loaded with 1μM of the cell permeable calcium sensitive dye, Fura-2AM (Life
Technologies, USA) for 30 minutes and washed with PBS before imaging. Coverslips contain-
ing cells are placed in a chamber with constant infusion of PBS at room temperature as indi-
cated below. Perfusion conditions for Be2C cells are: 1 min PBS; 59 min 10μMmorphine
(NIH/NIDA, USA). Fluorescence is detected by a Nikon Eclipse TI microscope at 340 and 380
nm wavelengths and analyzed with the TI Element Software (Nikon, Japan). Cells are consid-
ered as responsive to a drug infusion if the 340/380 ratio is 0.2 from baseline. Mean values
are compared using one-ANOVA and Fisher’s LSD. Expression levels of 7TM-, and 6TM-
mOR in Be2C cells are comparable with what previously characterized by Gris et al. using
RT-PCR [16].
Electrophysiology measurements
One day prior to transfection, Be2C cells are plated at ~50% confluency onto 35 mm plastic
dishes. Cells are transiently transfected with a 7TM-mOR-containing eGFP plasmid, 6TM-
mOR-containing eGFP plasmid, or an empty eGFP control plasmid using FuGene 6 (Pro-
mega). Transfections are carried out according to manufacturer’s instructions using 2 μg of
DNA. Cells co-transfected with 6TM-mOR, and the β2AR receptor-tdTomato fusion gene,
receive 1 μg of each plasmid. One day following transfection, cells are plated onto 35 mm glass
bottom dishes. Whole-cell patch clamp recordings are made 48 hours after transfection. Exter-
nal solution contains: 140 mM NaCl, 3 mM KCl, 1 mMMgCl2, 10 mMHEPES, 2 mM CaCl2,
and 10 mM glucose (pH 7.4, 294 mOsm). The internal pipette solution consists of 123 mM K-
gluconate, 10mM KCl, 1 mMMgCl2, 10 mMHEPES, 1 mM EGTA, 0.1 mM CaCl2, 1 mM
K2ATP, 0.2 mM Na4ATP, and 4 mM glucose (pH 7.2, 302 mOsm). For treated cells, morphine
(10 μM) is added to growth medium 1 hour before recordings. Current-voltage (I-V) plots are
determined by recording the current response to voltage steps ranging from -90 to +50 mV in
10 mV increments from a holding potential of -70 mV. All recordings are performed with an
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Axon MultiClamp 700B amplifier (Molecular Devices) using non-coated glass pipettes (2.5–5
MO). Clampex 10.3 (Molecular Devices) is used for data acquisition. Data analysis and figure
preparation was performed using Clampfit 10.3 (Molecular Devices) and Microsoft Excel.
Supporting Information
S1 Fig. Inter-atomic distances between morphine and 7TM-mOR. Average (in black) and
standard deviation (cyan) of distances between atoms of morphine (in red at the top) and
amino acids in 7TM-mOR binding site are reported. Specifically, from top to bottom in the left
column: morphine-C14-A117-Cβ, morphine-N11-D147-Cγ, morphine-N150-Cγ, morphine-
M151-Cβ, and morphine-C2-W293-Cβ. From top to bottom in the right column: morphine-
C3-I296-Cβ, morphine-O21-H297-Nδ, morphine-C16-I322-Cβ, morphine-C15-G235-Cα,
and morphine-C8-Y236-Cβ. Analyses are performed on the last 40 ns of simulations of three
independent simulations.
(PDF)
S2 Fig. Inter-atomic distances between morphine and 6TM-mOR. Average (in black) and
standard deviation (cyan) of distances between atoms of morphine (in red at the top) and
amino acids in 6TM-mOR binding site are reported. Specifically, from top to bottom in the left
column: morphine-C14-A117-Cβ, morphine-N11-D147-Cγ, morphine-N150-Cγ, morphine-
M151-Cβ, and morphine-C2-W293-Cβ. From top to bottom in the right column: morphine-
C3-I296-Cβ, morphine-O21-H297-Nδ, morphine-C16-I322-Cβ, morphine-C15-G235-Cα,
and morphine-C8-Y236-Cβ. Analyses are performed on the last 40 ns of simulations of three
independent simulations.
(PDF)
S3 Fig. Similarity of morphine bound conformations in 7TM- and 6TM-mOR. A) Superim-
position of morphine binding mode in 7TM- (green) and 6TM-mOR (blue) as obtained with
MedusaDock (t = 0 ns). The energy of binding, estimated using MedusaScore, is equal to -40.3
kcal/mol and -39.5 kcal/mol for 7TM-mOR and 6TM-mOR, respectively. The RMSD of super-
imposed conformations is ~ 0.3 Å. B) Superimposition of the lowest energy bound conforma-
tions of morphine in 7TM- (green) and 6TM-mOR (blue) obtained from three independent
MD simulations. No clustering analysis has been performed for the selection of bound confor-
mations because of the persistence of morphine coordinates within the crystallographic resolu-
tion of the receptor along the entire MD simulation (i.e., 2.8 Å, Fig 1A). The energy of binding
of the final conformations (t = 60 ns), estimated using MedusaScore, is equal to -42.9 kcal/mol
and -46.5 kcal/mol for 7TM-mOR and 6TM-mOR, respectively. The RMSD of superimposed
conformations is ~ 1.3 Å. Residue labels are reported only in the left figure.
(PDF)
S4 Fig. Morphinan core orientation of morphine and β-FNA in complex with 7TM-mOR.
A) Chemical structures of morphine (left) and β-FNA (right), in which the morphinan core is
highlighted in red. B) Superimposition of MedusaDock docking solution of morphine (green)
to the crystallographic conformation of β-FNA covalently bound to K233 in 7TM-mOR bind-
ing site. C) Superimposition of previously published docking solution of morphine [7] (orange)
to the crystallographic conformation of β-FNA covalently bound to K233 in 7TM-mOR bind-
ing site. In (B) and (C) mOR electron density map as available from the Electron Density
Server (ref. [53] in the main text) is reported as white mesh.
(PDF)
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S5 Fig. Western blot analysis of HEK293 cell total lysates using antibodies against FLAG
tag. Cells were transiently transfected with FLAG-tagged 7TM-, 6TM-mOR, or empty vector.
48h after cells were lysed with RIPA lysis buffer (ThermoFisher Scientific); protein concentra-
tions were determined with the BCA protein assay kit (ThermoFisher Scientific) and 20 μg
lysates were loaded per lane for a SDS-PAGE gel separation. WB: probing antibody.
(PDF)
S1 Table. Root mean square distances among docking solutions.
(DOCX)
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